In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 81 to 90 of 293

TitleTypeExpected publication date
Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097]Technology appraisal guidanceTBC
Efgartigimod for treating chronic inflammatory demyelinating polyneuropathy [ID6409]Technology appraisal guidance
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]Technology appraisal guidanceTBC
Elamipretide for treating Barth syndrome in people of any age [ID6545]Technology appraisal guidanceTBC
Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over [TSID11847]Technology appraisal guidanceTBC
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]Technology appraisal guidance
Epcoritamab with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6586]Technology appraisal guidance
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]Technology appraisal guidanceTBC
Etripamil for treating paroxysmal supraventricular tachycardia [ID6581]Technology appraisal guidanceTBC
Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke [TSID11920]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All